The FDA has approved PureTech Health’s ‘space occupying’ device Plenity as a new prescription treatment for obesity, setting it up to rival Novo Nordisk in this lucrative market.
US-based Vedanta Biosciences has raised $27 million in a Series C financing to investigate microbiome-derived therapies for several indications, including cancer and
US biotech PureTech Health has signed a potential billion-dollar deal with Roche based around its exosome technology that allows for oral administration of complex payloads – in this case a
PureTech Health is to develop a combination of a microbiome treatment with checkpoint inhibitor immunotherapy to enhance the effect of the cancer drugs.
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.
